ANZUP at ASCO 2025 – TheraP

Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177Lu-PSMA-617 or cabazitaxel: an exploratory post-hoc analysis of a randomized phase II trial

Oral presentation by Dr Asli Munzur. Clonal haematopoiesis occurs when there is abnormal expansion of clonal hematopoietic (blood forming) stem cells that occurs with age or via cellular mutation and is a condition that can lead to blood cancers, cardiovascular disease and increased mortality. Dr Asli Munzur presented fundings from a sub-study of the TheraP trial which showed that treatment with the radioligand therapy LuPSMA was associated with a higher incidence of clonal hematopoiesis mutations compared to cabazitaxel chemotherapy. While more research is needed, the study highlighted the importance of understanding the risks of hematological conditions (eg blood cancers) when considering LuPSMA treatment.